<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1294</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>9</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2019-10-30</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Synergy of Chemo- and Photodynamic Therapies with C60 Fullerene-Doxorubicin Nanocomplex</title>
    <abstract language="eng">A nanosized drug complex was explored to improve the efficiency of cancer chemotherapy, complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts of a non-covalent nanocomplex of Doxorubicin (Dox) with carbon nanoparticle C60 fullerene (C60) were applied in 1:1 and 2:1 molar ratio, exploiting C60 both as a drug-carrier and as a photosensitizer. The fluorescence microscopy analysis of human leukemic CCRF-CEM cells, in vitro cancer model, treated with nanocomplexes showed Dox’s nuclear and C60’s extranuclear localization. It gave an opportunity to realize a double hit strategy against cancer cells based on Dox’s antiproliferative activity and C60’s photoinduced pro-oxidant activity. When cells were treated with 2:1 C60-Dox and irradiated at 405 nm the high cytotoxicity of photo-irradiated C60-Dox enabled a nanomolar concentration of Dox and C60 to efficiently kill cancer cells in vitro. The high pro-oxidant and pro-apoptotic efficiency decreased IC50 16, 9 and 7 × 103-fold, if compared with the action of Dox, non-irradiated nanocomplex, and C60’s photodynamic effect, correspondingly. Hereafter, a strong synergy of therapy arising from the combination of C60-mediated Dox delivery and C60 photoexcitation was revealed. Our data indicate that a combination of chemo- and photodynamic therapies with C60-Dox nanoformulation provides a promising synergetic approach for cancer treatment.</abstract>
    <parentTitle language="eng">Nanomaterials</parentTitle>
    <identifier type="issn">2079-4991</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-12940</identifier>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.date">2019-12-13T01:52:58+00:00</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">f988bbe021d54d197e59d010cfa1917a</enrichment>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Chepurna, O., Grebinyk, S., Prylutskyy, Y., Ritter, U., et al. (2019). Synergy of Chemo- and Photodynamic Therapies with C60 Fullerene-Doxorubicin Nanocomplex Nanomaterials. 9 (11), 1540.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/nano9111540</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Oksana Chepurna</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Tymish Y. Ohulchanskyy</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>photodynamic chemotherapy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>synergistic effect</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>nanocomplex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1294/nanomaterials-09-01540.pdf</file>
  </doc>
  <doc>
    <id>1096</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>14</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro</title>
    <abstract language="eng">Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C60 fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.&#13;
&#13;
Here, we studied the physicochemical properties and anticancer activity of C60 fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C60-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed ≤ 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug’s level evidenced C60 fullerene considerable nanocarrier function.&#13;
&#13;
The results of this study indicated that C60 fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.</abstract>
    <parentTitle language="eng">Nanoscale Research Letters</parentTitle>
    <identifier type="issn">1556-276X</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-10966</identifier>
    <note>Das Dokument wurde zurückgezogen. Die korrigierte Version ist unter dem folgenden Link zu finden: https://nbn-resolving.org/urn:nbn:de:kobv:526-opus4-11415</note>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Grebinyk, S. et al. Nanoscale Res Lett (2019) 14: 61. https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <enrichment key="RelatedIdentifier">https://nbn-resolving.org/urn:nbn:de:kobv:526-opus4-11415</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent complex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>accumulation</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
  </doc>
  <doc>
    <id>1141</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>14</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro</title>
    <abstract language="eng">Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C60 fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.&#13;
&#13;
Here, we studied the physicochemical properties and anticancer activity of C60 fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C60-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed ≤ 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug’s level evidenced C60 fullerene considerable nanocarrier function.&#13;
&#13;
The results of this study indicated that C60 fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.</abstract>
    <parentTitle language="eng">Nanoscale Research Letters</parentTitle>
    <identifier type="issn">1556-276X</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-11415</identifier>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Grebinyk, S. et al. Nanoscale Res Lett (2019) 14: 61. https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent complex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>accumulation</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1141/2019_NRL_Grebinyk.pdf</file>
  </doc>
  <doc>
    <id>1477</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>conferenceobject</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">LED-based portable light source for photodynamic therapy</title>
    <abstract language="eng">Photodynamic therapy (PDT) employs light activation of tissue-localized photosensitizer in an oxygen-dependent process which initiates oxidative stress, inflammation, and cell death. Laser systems, which are mostly used in PDT as light sources can be costly and oversized. light-emitting diodes (LEDs) equipment has a high potential to simplify technical part of phototriggered therapies and to reduce its costs. We develop the LED-based system that includes the control and irradiation units. The system provides the same power density at any irradiation point. Among the advantages of the device is a possibility to change the irradiation area and tune the irradiation dose. PDT experiments with cancer cells in vitro treated with two different photosensitizers demonstrated a possibility to use the developed LED-based system as a low-cost light source in PDT.</abstract>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-14778</identifier>
    <enrichment key="opus.import.date">2021-08-26T11:19:53+00:00</enrichment>
    <enrichment key="opus.source">sword</enrichment>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.file">filename=phpCgvAlh</enrichment>
    <enrichment key="opus.import.checksum">c2d415e2348cf5f248f3ea95b8aac99c</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1117/12.2541774</enrichment>
    <enrichment key="SourceTitle">O. Chepurna, A. Grebinyk, Yu. Petrushko, S. Prylutska, S. Grebinyk, V. M. Yashchuk, O. Matyshevska, U. Ritter, T. Dandekar, M. Frohme, J. Qu, and T. Y. Ohulchanskyy, "LED-based portable light source for photodynamic therapy", Proc. SPIE 11190, Optics in Health Care and Biomedical Optics IX, 111901A (20 November 2019); https://doi.org/10.1117/12.2541774</enrichment>
    <enrichment key="CopyrightInfo">Copyright 2019 Society of Photo-Optical Instrumentation Engineers (SPIE). One print or electronic copy may be made for personal use only. Systematic reproduction and distribution, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.</enrichment>
    <licence>Das Dokument ist urheberrechtlich geschützt.</licence>
    <author>Oksana Chepurna</author>
    <author>Anna Grebinyk</author>
    <author>Yulia Petrushko</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Valeriy Yashchuk</author>
    <author>Olga Matyshevska</author>
    <author>Uwe Ritter</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <author>Junle Qu</author>
    <author>Tymish Y. Ohulchanskyy</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>light source</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>high power single chip LED</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>photodynamic therapy</value>
    </subject>
    <collection role="ddc" number="621">Angewandte Physik</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="green_open_access" number="2">Green Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1477/111901A.pdf</file>
  </doc>
  <doc>
    <id>1293</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>11</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2019-11-08</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells</title>
    <abstract language="eng">A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern, and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet, its poor water solubility, stability, and bioavailability hinder clinical application. In this study, we have explored a nanosized carbon nanoparticle—C60 fullerene (C60)—for optimized Ber delivery into leukemic cells. Water dispersions of noncovalent C60-Ber nanocomplexes in the 1:2, 1:1, and 2:1 molar ratios were prepared. UV–Vis spectroscopy, dynamic light scattering (DLS), and atomic force microscopy (AFM) evidenced a complexation of the Ber cation with the negatively charged C60 molecule. The computer simulation showed that π-stacking dominates in Ber and C60 binding in an aqueous solution. Complexation with C60 was found to promote Ber intracellular uptake. By increasing C60 concentration, the C60-Ber nanocomplexes exhibited higher antiproliferative potential towards CCRF-CEM cells, in accordance with the following order: free Ber &lt; 1:2 &lt; 1:1 &lt; 2:1 (the most toxic). The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM cells treated with C60-Ber nanocomplexes evidenced apoptosis induction. Thus, this study indicates that the fast and easy noncovalent complexation of alkaloid Ber with C60 improved its in vitro efficiency against cancer cells.</abstract>
    <parentTitle language="eng">Pharmaceutics</parentTitle>
    <identifier type="issn">1999-4923</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-12932</identifier>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.date">2019-12-12T23:05:01+00:00</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">d3b76ebd17631c1dd7d3f3f0bd6f6ea4</enrichment>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Buchelnikov, A., Tverdokhleb, N., Grebinyk, S., Evstigneev, M., et al. (2019). C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells Pharmaceutics. 11 (11), 586.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/pharmaceutics11110586</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Anatoliy Buchelnikov</author>
    <author>Nina Tverdokhleb</author>
    <author>Sergii Grebinyk</author>
    <author>Maxim Evstigneev</author>
    <author>Olga Matyshevska</author>
    <author>Vsevolod Cherepanov</author>
    <author>Yuriy Prylutskyy</author>
    <author>Valeriy Yashchuk</author>
    <author>Anton Naumovets</author>
    <author>Uwe Ritter</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent nanocomplex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>UV–Vis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>DLS and AFM measurements</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>drug release</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>uptake</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1293/pharmaceutics-11-00586-v2.pdf</file>
  </doc>
</export-example>
